➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Mallinckrodt

Last Updated: April 22, 2021

DrugPatentWatch Database Preview

REPATHA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for REPATHA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Annapoorna KiniPhase 4
Azienda Ospedaliera Ordine Mauriziano di TorinoPhase 4
Korea University Anam HospitalPhase 4

See all REPATHA clinical trials

Recent Litigation for REPATHA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Amgen Inc. v. Sanofi2017-01-11
Amgen Inc. v. Sanofi2014-11-16

See all REPATHA litigation

Pharmacology for REPATHA
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionPCSK9 Inhibitors

Company Disclosures: US Patents for REPATHA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen, Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen, Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen, Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for REPATHA

These patents were identified by searching patent claims

Supplementary Protection Certificates for REPATHA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1690026-8 Sweden   Start Trial PRODUCT NAME: EVOLOCUMAB; REG. NO/DATE: EU/1/15/1016 20150721
93096 Luxembourg   Start Trial PRODUCT NAME: EVOLOCUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (REPATHA); FIRST REGISTRATION DATE: 20150721
PA2016025 Lithuania   Start Trial PRODUCT NAME: ALIROKUMABAS; REGISTRATION NO/DATE: EU/1/15/1031 20150923
1690035-9 Sweden   Start Trial PRODUCT NAME: ALIROKUMAB; REG. NO/DATE: EU/1/15/1031 20150925
93180 Luxembourg   Start Trial PRODUCT NAME: ALIROCUMAB OU UN DERIVE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (PRALUENT); FIRST REGISTRATION DATE: 20150923
122016000042 Germany   Start Trial PRODUCT NAME: EVOLOCUMAB; REGISTRATION NO/DATE: EU/1/15/1016 20150717
PA2016021 Lithuania   Start Trial PRODUCT NAME: EVOLOCUMABUM; REGISTRATION NO/DATE: EU1/15/1016 20150717
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Dow
Express Scripts
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.